Circulating Apelin-17 and Elabela Levels as Predictive Biomarkers of Neurodegeneration and Cognitive Decline in Alzheimer’s Disease

Background: Alzheimer’s disease is characterized by progressive neurodegeneration and cognitive decline. Early diagnosis and monitoring are critical but remain challenging. Apelin-17 and Elabela, endogenous ligands of the apelin receptor (APJ), have emerged as neuroprotective peptides with potential...

Full description

Saved in:
Bibliographic Details
Main Authors: Shaimaa Imad Ali, Alabbas Majeed
Format: Article
Language:English
Published: College of Medicine, Al-Nahrain University 2025-07-01
Series:Baghdad Journal of Biochemistry and Applied Biological Sciences
Subjects:
Online Access:https://bjbabs.org/index.php/bjbabs/article/view/407
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849316564823703552
author Shaimaa Imad Ali
Alabbas Majeed
author_facet Shaimaa Imad Ali
Alabbas Majeed
author_sort Shaimaa Imad Ali
collection DOAJ
description Background: Alzheimer’s disease is characterized by progressive neurodegeneration and cognitive decline. Early diagnosis and monitoring are critical but remain challenging. Apelin-17 and Elabela, endogenous ligands of the apelin receptor (APJ), have emerged as neuroprotective peptides with potential biomarker utility. Objective: To evaluate circulating Apelin-17 and Elabela levels as predictive biomarkers of neurodegeneration and cognitive impairment in Alzheimer’s disease. Methods: We measured plasma Apelin-17 and Elabela in 60 Alzheimer’s disease patients and 60 cognitively normal controls. Correlations with cognitive scores, CSF AD biomarkers (Aβ42, total tau, phosphorylated tau), inflammatory markers (IL-6, TNF-α, CRP), and MRI volumetric data were assessed. A subset (n=30) was followed longitudinally for 12 months. Results: Alzheimer’s disease patients showed significantly reduced Apelin-17 (48.7 ± 15.3 pg/mL vs. 82.1 ± 20.4 pg/mL) and Elabela levels (31.5 ± 9.8 pg/mL vs. 57.3 ± 14.1 pg/mL; p < 0.001 for both). Peptide levels correlated positively with MMSE and specific cognitive domains and inversely with CSF tau, inflammatory markers, and brain atrophy (hippocampus, entorhinal, parietal cortex). Baseline peptides predicted 12-month cognitive decline and hippocampal volume loss. Combined biomarker models including Apelin-17, Elabela, and classical markers improved diagnostic accuracy (AUC=0.93). Conclusion: Circulating Apelin-17 and Elabela are promising predictive biomarkers for neurodegeneration and cognitive decline in Alzheimer’s disease, reflecting multiple pathological processes. They hold potential for early diagnosis, monitoring, and therapeutic targeting.
format Article
id doaj-art-53f7a5b7f1304ff68dccde30a261f892
institution Kabale University
issn 2706-9915
language English
publishDate 2025-07-01
publisher College of Medicine, Al-Nahrain University
record_format Article
series Baghdad Journal of Biochemistry and Applied Biological Sciences
spelling doaj-art-53f7a5b7f1304ff68dccde30a261f8922025-08-20T03:51:43ZengCollege of Medicine, Al-Nahrain UniversityBaghdad Journal of Biochemistry and Applied Biological Sciences2706-99152025-07-016316817510.47419/bjbabs.v6i3.407Circulating Apelin-17 and Elabela Levels as Predictive Biomarkers of Neurodegeneration and Cognitive Decline in Alzheimer’s DiseaseShaimaa Imad Ali0https://orcid.org/0000-0001-6799-8053Alabbas Majeed1https://orcid.org/0009-0008-2609-1840Department of Chemistry, College of science, Al-Nahrain University, Jadriya, Baghdad, IraqDepartment of Molecular and Medical Biotechnology, College of Biotechnology, Al-Nahrain University, Baghdad, Iraq.Background: Alzheimer’s disease is characterized by progressive neurodegeneration and cognitive decline. Early diagnosis and monitoring are critical but remain challenging. Apelin-17 and Elabela, endogenous ligands of the apelin receptor (APJ), have emerged as neuroprotective peptides with potential biomarker utility. Objective: To evaluate circulating Apelin-17 and Elabela levels as predictive biomarkers of neurodegeneration and cognitive impairment in Alzheimer’s disease. Methods: We measured plasma Apelin-17 and Elabela in 60 Alzheimer’s disease patients and 60 cognitively normal controls. Correlations with cognitive scores, CSF AD biomarkers (Aβ42, total tau, phosphorylated tau), inflammatory markers (IL-6, TNF-α, CRP), and MRI volumetric data were assessed. A subset (n=30) was followed longitudinally for 12 months. Results: Alzheimer’s disease patients showed significantly reduced Apelin-17 (48.7 ± 15.3 pg/mL vs. 82.1 ± 20.4 pg/mL) and Elabela levels (31.5 ± 9.8 pg/mL vs. 57.3 ± 14.1 pg/mL; p < 0.001 for both). Peptide levels correlated positively with MMSE and specific cognitive domains and inversely with CSF tau, inflammatory markers, and brain atrophy (hippocampus, entorhinal, parietal cortex). Baseline peptides predicted 12-month cognitive decline and hippocampal volume loss. Combined biomarker models including Apelin-17, Elabela, and classical markers improved diagnostic accuracy (AUC=0.93). Conclusion: Circulating Apelin-17 and Elabela are promising predictive biomarkers for neurodegeneration and cognitive decline in Alzheimer’s disease, reflecting multiple pathological processes. They hold potential for early diagnosis, monitoring, and therapeutic targeting.https://bjbabs.org/index.php/bjbabs/article/view/407alzheimer’s diseaseapelin-17elabelail-6tnf-α
spellingShingle Shaimaa Imad Ali
Alabbas Majeed
Circulating Apelin-17 and Elabela Levels as Predictive Biomarkers of Neurodegeneration and Cognitive Decline in Alzheimer’s Disease
Baghdad Journal of Biochemistry and Applied Biological Sciences
alzheimer’s disease
apelin-17
elabela
il-6
tnf-α
title Circulating Apelin-17 and Elabela Levels as Predictive Biomarkers of Neurodegeneration and Cognitive Decline in Alzheimer’s Disease
title_full Circulating Apelin-17 and Elabela Levels as Predictive Biomarkers of Neurodegeneration and Cognitive Decline in Alzheimer’s Disease
title_fullStr Circulating Apelin-17 and Elabela Levels as Predictive Biomarkers of Neurodegeneration and Cognitive Decline in Alzheimer’s Disease
title_full_unstemmed Circulating Apelin-17 and Elabela Levels as Predictive Biomarkers of Neurodegeneration and Cognitive Decline in Alzheimer’s Disease
title_short Circulating Apelin-17 and Elabela Levels as Predictive Biomarkers of Neurodegeneration and Cognitive Decline in Alzheimer’s Disease
title_sort circulating apelin 17 and elabela levels as predictive biomarkers of neurodegeneration and cognitive decline in alzheimer s disease
topic alzheimer’s disease
apelin-17
elabela
il-6
tnf-α
url https://bjbabs.org/index.php/bjbabs/article/view/407
work_keys_str_mv AT shaimaaimadali circulatingapelin17andelabelalevelsaspredictivebiomarkersofneurodegenerationandcognitivedeclineinalzheimersdisease
AT alabbasmajeed circulatingapelin17andelabelalevelsaspredictivebiomarkersofneurodegenerationandcognitivedeclineinalzheimersdisease